Barclays’s Kiora Pharmaceuticals KPRX Stock Holding History

Barclays’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14	Closed	-$23K	–	7131
2018 Q3	$23K	Buy	14 +2	+17%	+$5.37K	﹤0.01%	6428
2018 Q2	$35K	Buy	12 +2	+20%	+$5.64K	﹤0.01%	5866
2018 Q1	$20K	Buy	+10	New	+$43.2K	﹤0.01%	6435

Other funds holding KPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays's KPRX Position: Q4 2018 in Review

Barclays sold out of Kiora Pharmaceuticals (KPRX) in Q4 2018, closing a stake of 14 shares — an estimated $23K sold.

Barclays first reported a position in KPRX in Q1 2018 and held it in 3 quarters. The position peaked at $35K in Q2 2018. 13 funds tracked by Wall St. Rank hold KPRX as of Q4 2018.

Barclays reported no remaining Kiora Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Barclays sold 14 Kiora Pharmaceuticals shares in Q4 2018, an estimated $23K.
Barclays first reported a position in Kiora Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Barclays's Kiora Pharmaceuticals position peaked at $35K in Q2 2018.
13 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2018.

Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.